Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹233 Cr
verified against source
Revenue YoY
-8%
reported change
EBITDA
₹68.98 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Archean Chemical's Q2 FY26 consolidated revenue declined 8% YoY to ₹239.6 crore, with EBITDA down 15% to ₹69 crore, reflecting a 28.8% margin. The miss was driven by lower bromine production due to technical issues and prolonged monsoon, partially offset by robust industrial salt volumes of 0.9 million tons. Management maintained its FY26 salt volume guidance of 4.5 million tons and expects bromine volumes to recover in H2. The semiconductor project received cabinet approval with a ₹2,067 crore Phase 1 investment, but near-term earnings remain pressured by delayed bromine derivative ramp-up and slow progress at Orin Hydrocarbons. Key risk: continued operational setbacks in bromine and derivatives could further delay volume recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated the full-year volume target despite Q2 shortfall due to monsoon, expecting to achieve it in H2.
- Current utilization is 30-35%; improvement expected as client approvals come through.
- Plant trials in Q4 FY26; full-fledged production expected after monsoon next year.
- Fiscal support agreement signing in advanced stage; project timeline ~30 months.
Risks flagged
- Technical issues and erratic monsoon have led to lower bromine volumes; corrective measures may take time to yield results.
- Acquisition challenges and slow client onboarding have pushed meaningful revenue contribution to FY27, 6 months behind schedule.
- Company has no prior experience in semiconductor manufacturing; reliance on consultants and technology partners.
- Despite capex of ₹190 crore, utilization is only 30-35% due to slow client approvals and low crude prices affecting rig activity.
Key quotes
- On orin it has been disappointingly slow. Ideally we should have already been able to start sales by now... we are 6 months behind than where we want to ideally be.
- We have almost 10,000 tons plus backlog in orders. So yes, it's two sides of the same coin.
- What gives us confidence that you'll be able to commercialize semiconductor chemicals which is probably a rather new area for altogether?
Research modules